Integromics
Granada · Founded 2002
About Integromics
Integromics (ITG) develops state-of-the-art software solutions for Life Sciences (Genomics and Proteomics) that enable scientists to effectively organize their data, perform advanced validated analyses, and discover new biomedical knowledge. ITG operates in the global Life Sciences market and has established a network of collaborations and partnerships that has enabled it to access the top-league of players in its sector, as proven by the names of its corporate clients, such as Pfizer, Novartis, Unilever, Merck, Sanofi-Aventis, and Amgen or institutional customers like ETH Zürich, Harvard Medical School, Chinese University of Hong Kong to cite only a few. Since its foundation in 2002, ITG has performed a spectacular, though organic, growth and is currently in a position to further embrace, not only the high-potential bioinformatics market and to consolidate its presence as a leading brand in the Life Sciences community, but also to expand in the personalized genomics clinical market.
Company Facts
- Founded: 2002
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $1.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2009)
- Website: http://www.integromics.com
- Phone: +34 91 585 53 05
Industries & Categories
Biotechnology, Data Management, Genetics, Health Care, Software
Social Profiles
Canonical: https://fsome.com/organization/integromics-1903859 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.